Determinants of drug delivery and transport to solid tumors
Introduction
Systemic and regional chemotherapy are used in the management of cancer patients. Following a systemic intravenous injection, drug delivery to the tumor core involves three processes, i.e. distribution through vascular space, transport across microvessel walls, and diffusion through interstitial space within the tumor tissue [1]. When the drug is directly injected into a tumor such as by intratumoral injection or by direct instillation into peritumoral space such as in intravesical therapy of superficial bladder cancer and in intraperitoneal dialysis of ovarian cancer, drug delivery to tumor cells is primarily by diffusion through interstitial space [2], [3], [4], [5].
An earlier presentation in this symposium discussed the importance of interstitial pressure in drug delivery after a systemic treatment. The present presentation addresses the barriers and determinants and the importance of drug-induced apoptosis in drug transport and delivery to solid tumors. The roles of interstitial space, drug removal by capillaries, tissue structure and tissue composition on drug distribution in organ and solid tumors are discussed.
Section snippets
Drug distribution in organs
We have completed a series of studies that evaluated the drug distribution on an organ level. We first studied the penetration of several drugs into bladder tissues during intravesical therapy or after the drug is instilled directly into the bladder cavity [5], [6], [7], [8]. These drugs, i.e. mitomycin C, doxorubicin, 5-fluorouridine and paclitaxel, have different physicochemical properties. These compounds show similarities as well as differences in their ability to penetrate the bladder. The
Barriers to drug distribution in organs
Confocal microscopy was used to evaluate the sub-organ barriers to drug distribution in several organs including bladder, prostate and tongue. Fig. 3 shows the distribution of doxorubicin in a dog bladder, after an intravesical dose. The results show uneven drug distribution throughout the bladder, with high drug concentration localized in the interstitial space adjacent to the blood vessels. In comparison, the remaining bladder tissues showed 3- to 5-fold lower drug concentrations. These data
Determinants of drug distribution in solid tumors
Many anticancer drugs exert their action by binding to macromolecules. Earlier studies using tumor cell spheroids have shown that penetration of protein-binding drugs such as doxorubicin and paclitaxel is limited to the periphery [9], [10], [11], [12], [13]. To identify the determinants of distribution of these protein-binding drugs, we used in vitro systems to study the time course of drug penetration, so that the results are not confounded by the effect of blood flow on drug transfer. Most of
Methods to improve drug delivery to tumors
Based on the above observations, we hypothesize a strategy where an apoptosis-inducing pretreatment is used to enhance the delivery of a protein-bound drug to solid tumors. This hypothesis was tested by in vitro and in vivo studies, using paclitaxel as the model drug. Three in vitro studies were performed using histocultures of human pharynx FaDu tumor xenograft. The first study evaluated the importance of apoptosis on paclitaxel penetration. This study used two concentrations of [3H]paclitaxel
Conclusions
With respect to drug distribution in organs, our results indicate that the kinetics of drug penetration from urine to bladder tissues, on an organ level, is described by the distributed model. Microscopic evaluation of the spatial drug distribution within several organs, i.e. bladder, prostate and tongue, indicates that drug distribution within these organs is heterogeneous with large and erratic concentration gradient. In general, drug distribution favors interstitial space and vasculature,
Acknowledgments
The work described in this manuscript is partly supported by research grants R37CA49816, R01CA63363 and R01CA74179 from the National Cancer Institute, NIH, DHHS.
References (26)
- et al.
Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids
Eur. J. Cancer
(1997) Delivery of molecular medicine to solid tumors
Science
(1996)- et al.
Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer
Semin. Oncol.
(1995) Intraperitoneal therapy of ovarian cancer
Semin. Oncol.
(1998)- et al.
Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies
Int. J. Cancer
(1997) - et al.
Bladder tissue pharmacokinetics of intravesical taxol
Cancer Chemother. Pharmacol.
(1997) - et al.
Penetration of intravesical doxorubicin in human bladders
Cancer Chemother. Pharmacol.
(1996) - et al.
Penetration of mitomycin C in human bladder
Cancer Res.
(1993) - et al.
Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine
Clin. Cancer Res.
(1997) Distribution and activity of antineoplastic drugs in a tumor model
J. Natl. Cancer Inst.
(1989)
Slow penetration of anthracyclines into spheroids and tumors: a therapeutical advantage
Cancer Chemother. Pharmacol.
Relationship between the penetration, binding and average concentration of cytostatic drugs in human tumor spheroids
Cancer Chemother. Pharmacol.
Penetration of substances into tumor tissue — a methodological study on cellular spheroids
In vitro
Cited by (154)
Synthesis and characterization of PnVCL grafted agar with potential temperature-sensitive delivery of Doxorubicin
2022, Journal of Drug Delivery Science and TechnologyCitation Excerpt :There are a lot of drugs which are highly capable of achieving this goal. Nevertheless, the main reason for the limitations in the application of chemotherapeutics is their nonselective toxicity [1]. The main challenge of anti-cancer therapy remains the ability to achieve a therapeutic dose at the tumor site [2] with sufficient circulation time without rapid elimination from the organism [3] while low toxicity in healthy tissues is maintained [2].
Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer
2021, European Journal of Pharmaceutics and BiopharmaceuticsEffect of vascular normalization on drug delivery to different stages of tumor progression: In-silico analysis
2020, Journal of Drug Delivery Science and Technology